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AnalysisBuilding Public-Private Research 
Partnerships in Troubled Times
The Indian government is launching a series of new initiatives to boost public-private research part-
nerships and to jumpstart science-driven economic growth. But will the current global economic 
downturn hamper these efforts?As the global economic slump impacts 
university endowments, industry research 
budgets, and philanthropic support 
worldwide, the focus is shifting to the role 
of government in sustaining the scientific 
enterprise. All eyes are currently focused 
on President Obama’s $787 billion stimu-
lus package to boost the US economy. 
This package contains a $21.5 billion 
provision for funding scientific research 
and infrastructure: $10 billion for the US 
National Institutes of Health and $3 billion 
for the US National Science Foundation.
In India, research and development 
(R&D) have always been a government 
enterprise, with little support from the 
private sector. Recently, the Indian gov-
ernment has launched a number of new 
initiatives to encourage researchers to 
collaborate more closely with industry. 
“We need a new wave of investment 
from the private sector so that young 
people will be encouraged to seek a 
career in science,” the Indian Prime 
Minister Manmohan Singh said in his 
address to the 96th Indian Science Con-
gress in January this year. Although India 
has remained largely unscathed by the 
current economic crisis, its economy is 
starting to slow, registering 5.3% growth 
for the last quarter of 2008 compared to 
7.6% for the penultimate quarter. So will 
India’s vigorous efforts to engage indus-
try in R&D be realized, given the current 
economic downturn?
Handholding Life Sciences 
 Research
With a 5 year (2007–2012) budget of $1.5 
billion, the Department of Biotechnol-
ogy (DBT) in New Delhi is India’s largest 
federal funding agency for the life sci-
ences. For the past 3 years, DBT has 
been engaging with industry with the 
goal of driving science-based economic 
growth. “This country is trying to move in a certain direction but it has no culture 
of angel funding,” says Maharaj K. Bhan, 
Secretary of DBT. Despite the economic 
downturn, Bhan plans to keep directing 
DBT’s resources toward several new ini-
tiatives in the hope of “unleashing a whole 
new generation of people and ideas.” 
Such initiatives include a 2 year $6.5 mil-
lion pilot program called the Biotechnol-
ogy Industry Research & Development 
Assistance Program (BIRAP), launched 
in September 2008. DBT set up BIRAP 
to manage its industry R&D programs 
and to provide strategic support includ-
ing intellectual property management, 
technology transfer, regulatory advice, 
and clinical and field trial support (for 
agricultural and medical biotechnology). 
After completion of the 2 year pilot study, 
BIRAP will become an independent not-
for-profit council called BIRAC that will 
manage 30% of the DBT budget set aside 
for public-private  partnerships.
Under a new 5 year $75 million scheme 
called the Biotechnology Industry Part-
nership Program (BIPP) launched in 
December 2008, DBT aims to fund high-
risk technologies and “breakthrough” 
research projects. Potential projects 
include pinpointing accurate biomarkers 
to identify tuberculosis drug candidates 
and developing diagnostics for HIV/
AIDS and hypertension. The first round 
of BIPP grant awards will be announced 
in the next month. To ensure commer-
cial success, BIPP will be managed by 
BIRAC, and DBT will be assisted by 
two industry bodies—the Association of 
Biotech Led Enterprises (ABLE) and the 
Biotech Consortium of India Ltd (a public 
company under the aegis of DBT). “It’s 
the first time government is recognizing 
that risk-taking leads to rewards and is 
setting aside taxpayers’ money to fund 
radical innovative ideas,” says Shrikumar 
Suryanarayanan, Director General of Cell 13ABLE. He emphasizes that government 
support is needed more than ever dur-
ing this current economic downturn as 
no company wants to fund risky product 
research. “There is no precedent and we 
have no model to copy. India is innovat-
ing to solve its problems,” he says.
BIPP will fund projects that are high-
risk but promising for the marketplace. 
For instance, notes Bhan, currently it is 
unimaginable for anyone in industry to 
come up with a tuberculosis or malaria 
vaccine program or even innovative 
ideas in stem cell research. “But with 
BIPP, they know where to go for money 
and guidance,” he notes. Projects under 
development that could fall within the 
scope of this initiative are vaccine can-
didates to protect against Japanese 
encephalitis, cholera, or rotavirus, a DNA 
vaccine for rabies, and tuberculosis drug 
candidates. “There are at least four or 
five good products out there [in] industry 
which have been developed in collabo-
ration with Indian research institutions. 
They need a lot of money to reach the 
market,” says Bhan. He believes that 
the biotech industry in India needs to 
be treated, at least for now, like the pub-
lic sector so that the products become 
accessible and affordable for the Indian 
population. In this respect, agricultural 
biotechnology will receive “aggressive” 
support, says Bhan. Agribiotech cur-
rently comprises <15% of India’s biotech 
revenue (which was $2.56 billion for the 
year ending March 2008) compared with 
67% revenue from biopharma. Describ-
ing oversight of BIPP, Bhan says, “even-
tually it will become a strong institu-
tion: DBT will focus on basic research, 
BIRAC on innovation and public-private 
 partnerships.”
DBT already runs a Small Business 
Innovation Research Initiative (SBIRI) 
launched in 2006 to fund promising 6, March 20, 2009 ©2009 Elsevier Inc. 987
early-stage research and has so far 
funded 48 projects. “These [BIPP, SBIRI, 
and BIRAP] are very innovative funding 
mechanisms to provide seed funding as 
well as risk capital to the biotech sector 
which was financially challenged even 
without the present economic crisis,” 
says Kiran Mazumdar-Shaw, founding 
chairman and managing director of Bio-
con Ltd, India’s largest biotechnology 
company. She points out that the need 
for government to engage with industry 
was realized 2 years ago and “what we 
are seeing today is the result of a clearly 
thought out strategy.”
Building Up India’s Human 
 Resources
A key element that may undermine India’s 
entire effort to jumpstart science-driven 
economic growth is a lack of human 
resources for research and manage-
ment. “Even though it is the best of times 
for biology research in India, the biggest 
bottleneck here is the poor density of 
researchers,” says Rajesh S. Gokhale, a 
Howard Hughes Medical Institute inter-
national scholar based at the National 
Institute of Immunology in New Delhi.
Several new initiatives have been 
launched to address this personnel 
shortage including the joint DBT-Well-
come Trust Biomedical Research Career 
Program, announced in September 2008. 
This 5 year £80 million initiative will fund 
cutting-edge biomedical research in 
India and will complement the Wellcome 
Trust’s existing investment in the country. 
This alliance will award 40 early career 
fellowships to Indian citizens working 
in India or abroad (and possibly also to 
non-Indian citizens who wish to pursue 
research in India), 20 intermediate fel-
lowships, and 15 senior research fellow-
ships annually, with the first awards to be 
handed out in May 2009. A major goal of 
this alliance is to woo Indian researchers 
working overseas to return to their home-
land and to set up independent labs. 
“We are very excited about the program 
as we think we have an opportunity to 
change the face of biomedical research 
in India,” says Jimmy Whitworth, head of 
international activities and science fund-
ing at the Wellcome Trust in London. In 
fact, researchers in India are already get-
ting inquires from those overseas offer-
ing to write joint grants, says Gokhale. 988 Cell 136, March 20, 2009 ©2009 Elsevie“The current availability of a vast num-
ber of opportunities in India has inten-
sified my efforts to return,” says Vivek 
Rao at the National Institute for Medical 
Research in London, who has applied for 
a Wellcome Trust-DBT intermediate fel-
lowship. Whitworth emphasizes that the 
quality of grants will be paramount and 
that the program will leave slots unfilled if 
the applications are not of a high enough 
standard. Whitworth predicts that most 
of the applications will be from research-
ers in molecular biology, physiology, 
genetics, immunology, infectious dis-
eases, and neuroscience.
These awards may prove particularly 
attractive to Indian neuroscientists work-
ing overseas as neuroscience is a new 
research area for India. The first neu-
roscience center in India, the National 
Brain Research Centre (NBRC), opened 
in 2000 in Manesar, Haryana. “Even 
though we knew 40 years ago that it was 
an important area, we somehow never 
paid attention to neuroscience,” says 
Vijayalakshmi Ravindranath, founding 
director of NBRC. She is now setting 
up another center at the Indian Institute 
of Science in Bangalore, the country’s 
largest basic science research institute. 
Ravindranath notes that the new center’s 
emphasis will be on “needs and niche”: 
childhood diseases and neurodegenera-
tive and cognitive disorders (which will 
leverage existing expertise in computa-
tional and electrical engineering). India, 
despite having a large population, has 
not paid much attention to diseases of 
aging such as Alzheimer’s and Parkin-
son’s diseases, says molecular bio-
physicist Avadhesha Surolia, director 
of the National Institute of Immunology. 
“We have not systematically screened 
a large section of the population to see 
what’s the incidence of these disorders,” 
he adds.
Even in tuberculosis, malaria, and 
leishmaniasis research, where Surolia 
and others think that India has been on 
the frontline, there have been few break-
throughs in the discovery and develop-
ment of new drugs. “India hasn’t been 
able to bridge the gap between discov-
ery and translation, we go for either of the 
two,” says Surolia. DBT aims to address 
this shortcoming by setting up Transla-
tional Health Science and Technology 
Institutes in four cities at a total cost of r Inc.~$25 million and with help from the Mas-
sachusetts Institute of Technology (MIT) 
in Cambridge, MA. “Funds for all centers 
have been allocated and a tremendous 
amount of global consultation is going 
on,” says Bhan.
In Search of Young Scientists
Encouraging young people to think about 
science as a long-term career is some-
thing that the Indian funding agencies, 
particularly DBT, have been grappling 
with. In November last year, Prime Minis-
ter Singh launched a 5 year $480 million 
scholarship program for one million 10- 
to 15-year-old Indian students, whose 
funding will continue through graduate 
school as long as they pursue a science 
career. This year, DBT will start an Igni-
tion Grant scheme in collaboration with 
MIT to fund postgraduates, who have 
ideas that could lead to products (or 
processes) but do not have a registered 
company or the infrastructure to put their 
ideas into action. This scheme would 
complement existing programs such 
as the Young Entrepreneurs Scheme, a 
collaboration with the UK’s Biotechnol-
ogy and Biological Sciences Research 
Council, and the Bio-design Program, a 
collaboration between Stanford Univer-
sity and the All India Institute of Medi-
cal Sciences in New Delhi. The Stanford 
Bio-design Program aims to train the 
next generation of medical technology 
innovators in areas such as diagnostics 
and imaging and has resulted in several 
patents. “We will have bilateral part-
nerships with countries that have good 
innovation programs and then ‘Indianize’ 
them to suit our conditions,” says Bhan, 
who is planning a long pipeline of similar 
initiatives including a biotech business 
plan competition for students in biology 
masters programs at Indian universities.
Most of the 300 or so universities in 
India have gradually become dissoci-
ated from research, which has increas-
ingly shifted to national labs and insti-
tutes. To address this problem, Prime 
Minister Singh recently announced that 
the government would launch a National 
Science and Engineering Research 
Board (NSERB) along the lines of the US 
National Science Foundation. “This is 
being set-up primarily to fund universi-
ties, where at the present time research is 
almost non-existent. It is very important 
to rejuvenate this sector but it cannot be 
done at the cost of existing set up,” says 
Surolia. However, the catch is that the 
launch of NSERB needs the approval of 
the Indian Parliament at a time when the 
country is in the throes of a national elec-
tion set to begin on April 16.
From Patents to Profits
In addition to its emphasis on collabora-
tions with industry and science educa-
tion, the Indian government is currently 
pondering legislation similar to the US 
Bayh-Dole Act of 1980 that promotes the 
patenting and commercialization of pub-
licly funded research. Called the Public 
Funded Research and Development Bill 
2007, this legislation is viewed as a way 
to encourage commercialization of uni-
versity research, to achieve benefits for 
society and revenue for institutions, and 
to drive competitiveness among institu-
tions. “This would empower the universi-
ties and bring some awareness among 
Indian researchers about intellectual 
property and its commercialization, which 
is largely lacking today,” says biophysicist 
Samir K. Bharmachari, Director General of 
India’s Council of Scientific Research and 
Industrial Research (CSIR). Indian institu-
tions have largely welcomed this legisla-tion, even though some believe that the 
impact of the Bayh-Dole Act on innova-
tion and economic growth in the US has 
been overstated. They argue that coun-
tries like India that are considering such 
legislation, or those like China, Brazil, and 
Malaysia that have recently passed similar 
legislation, need to introduce safeguards 
that prevent exclusive licensing of broad 
brush technologies that could eventually 
limit public benefits. The new legisla-
tion is unlikely to be approved before the 
national election begins next month.
Bharmachari says that there is a global 
shift in the intellectual property protection 
of publicly funded research. In 2007, CSIR 
(which files more patent applications than 
any other Indian research institute or uni-
versity) ranked eighth according to the 
World Intellectual Property Organization 
with 98 patent filings. In comparison, the 
University of California system is the top-
ranking publicly funded institution world-
wide with 364 filings. But the translation 
of Indian patents into marketable prod-
ucts remains low. To improve the com-
mercialization of discoveries, CSIR is set-
ting up a new body similar to Cambridge 
Enterprise of the University of Cambridge 
and Imperial Innovations of Imperial Col-
lege London in the UK.Cell 13Last month, the government granted an 
additional ~$150 million (for 2009–2012) 
to its existing Millennium Indian Technol-
ogy Leadership Initiative (NMITLI), which 
is managed by the CSIR. With this bud-
get, the program will now experiment 
with R&D public-private partnerships. 
Industry projects will be funded with co-
financing by venture capital, and there 
will be support for post-NMITLI projects 
so that they reach the marketplace. In 
addition, there is a provision to convert 
government loans into equity/shares as 
well as to involve international compa-
nies in R&D efforts.
Although this cluster of new and pend-
ing government initiatives is encour-
aging, Bhan emphasizes that they will 
“yield results over a decade” rather than 
in 1 or 2 years. Despite the economic 
slowdown, the Indian government is 
continuing its plans to allocate funds 
for R&D, to establish new organizations, 
and to define new rules of engagement 
for industry in the research enterprise. 
However, with the national election start-
ing next month and the full impact of the 
economic slowdown on the Indian econ-
omy yet to be determined, it remains to 
be seen whether India will continue along 
this bold new path.
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